
    
      This is a single centered, randomized, single blind phase II clinical study. Patients will be
      divided into two groups of case and control. Patients of case group will receive
      intra-articular injection of autologous BMSCs suspended in 3 ml autologous PRP for 3 times,
      patients of control group will receive intra-articular injection of 3 ml of autologous PRP
      for 3 times. The investigators designed this clinical study to evaluate therapeutic effects
      of BM-MSCs in patients with severe knee osteoarthritis.
    
  